Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.8750.

A number of research analysts have commented on SRTS shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Friday, July 17th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors have recently bought and sold shares of SRTS. Geode Capital Management LLC raised its stake in shares of Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after acquiring an additional 3,766 shares during the last quarter. Sachetta LLC increased its holdings in Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares during the period. Pacific Ridge Capital Partners LLC raised its position in Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares during the last quarter. Jane Street Group LLC bought a new position in Sensus Healthcare during the 4th quarter valued at approximately $79,000. Finally, State Street Corp lifted its holdings in Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after buying an additional 3,400 shares during the period. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Stock Up 0.3%

Shares of SRTS stock opened at $2.92 on Thursday. The business has a 50-day moving average price of $2.94 and a two-hundred day moving average price of $3.77. Sensus Healthcare has a 12-month low of $2.66 and a 12-month high of $5.66. The firm has a market cap of $48.06 million, a P/E ratio of -6.21 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.